NCT03385369

A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

A Phase 1, Randomized, Blinded, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: MedImmune LLC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a phase I, randomized, blinded study to evaluate the safety and pharmacokinetics of MEDI0382 following single dose administration to overweight/obese subjects of Japanese or Chinese descent

Detailed description

This is a phase I, randomized, blinded study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of MEDI0382 following single dose administration to overweight/obese but otherwise healthy adult male and female subjects of Japanese or Chinese descent

Conditions

• Safety
• Healthy Subjects

Interventions

Type	Name	Description
DRUG	MEDI0382	Single dose of MEDI0382
DRUG	Placebo	Single dose of placebo

Timeline

• Start date: 2018-01-05
• Primary completion: 2018-04-12
• Completion: 2018-04-12
• First posted: 2017-12-28
• Last updated: 2019-04-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study